NCT00052780 - Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

November 30, 2007

Conditions

Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma

Interventions

DRUG

O6-benzylguanine

Given IV

DRUG

temozolomide

Given PO

BIOLOGICAL

filgrastim

Given SC or IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

38105

Pediatric Brain Tumor Consortium, Memphis

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH